Gilgamesh Pharma Inc. is a clinical-stage neuroscience company that develops novel chemical entities to treat psychiatric diseases, aiming to move beyond symptom management toward rapid-acting and durable therapies. The company utilizes an AI-powered discovery platform and medicinal chemistry to create precision therapies targeting conditions such as depression, anxiety, addiction, and schizophrenia.
Subscribe to see Gilgamesh Pharma Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Gilgamesh Pharma Inc. is a biotechnology company headquartered in New York, United States. It has raised at least $87M across the 2 funding rounds on record. Its most recent funding round raised $60M in January 2026. Xcout tracks 7 named people at Gilgamesh Pharma Inc., including Jonathan Sporn (CEO).
As of 16 November 2026. Source: Xcout Intel.
1 more named person on record for Gilgamesh Pharma Inc., with roles, board committees and tenure — see the full roster →
At least $87M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $60M | — | |
| Series A | $27M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Gilgamesh Pharma Inc.'s closest competitors — see the full list of competitors and alternatives →
BlackThorn Therapeutics is a biotechnology company developing treatments for neuropsychiatric and neurological disorders, using computational biology, neuroscience, and clinical data to support drug discovery and development. Its work is aimed at patients with conditions such as depression and other disorders involving brain circuitry and behavior.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Psylo, Inc. is a biotechnology company focused on the discovery and development of next-generation neuroplastogens to treat psychiatric and neurological conditions. The company leverages medicinal chemistry and pharmacology to engineer safer, non-hallucinogenic psychedelic-inspired therapeutics. Its research and drug development efforts primarily serve patients suffering from treatment-resistant mental health disorders.
MindMed is a New York-based biopharmaceutical company focused on developing novel therapeutics for brain health disorders.
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Synendos Therapeutics is a clinical-stage biopharmaceutical and neuroscience company focused on developing a novel class of small molecules to treat psychiatric and neurological disorders.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Gilgamesh Pharma Inc.? Suggest a correction · Work at Gilgamesh Pharma Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.